Cullinan Therapeutics (CGEM) Total Current Liabilities (2020 - 2026)

Cullinan Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $35.2 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 28.54% year-over-year to $35.2 million in Q1 2026; TTM through Mar 2026 was $35.2 million, a 28.54% increase from a year earlier, with the FY2025 full-year figure at $37.7 million, up 23.15% from the prior year.
• Total Current Liabilities eased to $35.2 million in Q1 2026 per CGEM's latest filing, from $37.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $62.0 million in Q2 2022 and bottomed at $17.3 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $27.1 million (2022), against an average of $28.7 million.
• Across the five-year window, Total Current Liabilities jumped 980.18% in 2022 and sank 68.28% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $22.5 million in 2022, then grew by 25.06% to $28.1 million in 2023, then grew by 8.92% to $30.6 million in 2024, then advanced by 23.15% to $37.7 million in 2025, then fell by 6.85% to $35.2 million in 2026.
• Per Business Quant, the three latest CGEM Total Current Liabilities figures stand at $35.2 million (Q1 2026), $37.7 million (Q4 2025), and $32.8 million (Q3 2025).